Ọgwụgwọ ọhụrụ maka oke ibu

Sciwind Biosciences Co., Ltd., ụlọ ọrụ na-ahụ maka ọgwụ biopharmaceutical nke ụlọ ọgwụ lekwasịrị anya n'ịchọpụta na ịzụlite usoro ọgwụgwọ ọhụrụ iji gwọọ ọrịa metabolic, taa kwupụtara mmalite nke dosing onye ọrịa na nnwale ụlọ ọgwụ Phase 2b nke XW003 na ndị ọrịa nwere oke ibu.

Print Friendly, PDF & Email

XW003 bụ akwụkwọ akụkọ, glucagon na-adịte aka dị ka peptide-1 (GLP-1) nke emepụtara na Sciwind Biosciences. E gosiputara na ọ dị mma yana nnabata nke ọma, yana butere mbelata ịdị arọ dabere na dose na nnwale ụlọ ọgwụ n'oge.

Otu n'ime ọtụtụ etiti, randomized, labelụ mepere emepe, na-arụ ọrụ na-achịkwa usoro 2b na-eme atụmatụ ịtụle nchịkwa subcutaneous otu ugboro kwa izu nke XW003 n'ime ihe dịka ndị ọrịa 200 nwere oke ibu. Ndị sonyere na nnwale ahụ, nke a na-eme na Australia na New Zealand, ga-eji ọgwụ ọmụmụ ihe ruo izu 26, na-esote oge nleba anya na-enweghị ọgwụgwọ nke izu 5. Ebumnuche nke ọmụmụ a bụ iji nyochaa nchekwa, nnabata, na ịdị irè ọgwụgwọ XW003 na ndị ọrịa buru ibu. A na-atụ anya data kachasị elu na ọkara nke abụọ nke 2022. Na mgbakwunye, dị ka akụkụ nke mmemme mmepe zuru oke maka XW003, a na-emekwa nnwale dị iche iche na ndị ọrịa China nwere oke ibu.

"Obi dị anyị ụtọ ịnọgide na-enwe ọganihu ngwa ngwa nke XW003 site na mmepe ụlọ ọgwụ. Mmalite nke dosing ndidi n'ime a multi-center, mba ọmụmụ maka ọgwụgwọ nke oke ibu bụ ihe ọzọ dị mkpa dị ịrịba ama maka ụlọ ọrụ na a siri ike na-agba akaebe maka nraranye na ikike nke otu anyị," Dr. Hai Pan, onye nchoputa na CEO nke Sciwind kwuru. "Anyị kpebisiri ike na-aga n'ihu na mmepe nke XW003, yana ndị ọzọ na-achọ ọgwụ ọjọọ na pipeline Sciwind, maka ọgwụgwọ nke ọrịa metabolic, gụnyere oke ibu, ọrịa shuga, na NASH."

Print Friendly, PDF & Email

Akụkọ ndi ozo

Banyere chepụtara

nchịkọta akụkọ

Onye nchịkọta akụkọ nke eTurboNew bụ Linda Hohnholz. Ọ dabere na eTN HQ na Honolulu, Hawaii.

Ahapụ a Comment